Heads Up: Impact BioMedical Inc. (NYSE: IBO) Takes the #1 Spot on This Morning’s Watchlist

Sponsored* Next Potential Breakout: Impact BioMedical Inc. (NYSE: IBO) Takes the #1 Spot on the Market Crux Watchlist This Morning! Here’s Why You Should Consider Adding Impact BioMedical Inc. (NYSE: IBO) to Your Radar Today… Robust Intellectual Property Portfolio: With 39 issued patents and 50 pending applications, the company’s innovations are well-protected, ensuring a strong global competitive edge. Recent Market Momentum: Shares surged approximately 120% in one month, showcasing significant traction and market attention. Limited Float: With under 5.1M shares available, the company has the potential for significant shifts if demand begins to shift Targeting High-Growth Industries: The company is addressing markets collectively valued at over $324B by 2030, including oncology, neurology, antivirals, and sugar substitutes. Successful IPO: A recent listing on the NYSE American exchange highlights strong confidence in the company’s growth strategy and provides enhanced visibility and access to resources. November 18, 2024 Dear Reader, After our profile from late last week moved approximately 32% in under 24 hours, after closing at $2.51 (on 11/13) and reaching $3.33 on (11/14), it's time to take a look at our next potential breakout idea. Discovering, confirming, and patenting unique science and technologies, this company is driving new advancements in human healthcare.  With a recent IPO, a low float of around 5.1M shares, and an approximate 120% move last month, we’re excited to announce Impact BioMedical Inc. (NYSE: IBO) as our next potential breakout idea and the #1 focus on our watchlist for this morning. Impact BioMedical Inc. (NYSE: IBO) is leading the charge in health innovation, developing transformative solutions that address some of the most critical challenges in global healthcare.  From cutting-edge cancer treatments to antiviral therapies and consumer wellness breakthroughs, the company’s groundbreaking technologies are targeting high-value global markets with unmatched precision. At the core of its innovative portfolio is the groundbreaking Linebacker platform, a revolutionary technology that is redefining treatment possibilities in oncology and neurology. Linebacker Platform: Redefining Oncology and Neurology Treatments The Linebacker platform is a revolutionary approach that enhances the potency and bioavailability of polyphenols without compromising safety, offering unparalleled potential across a variety of applications: Lung Cancer: Addressing an Unmet Need in a $52.21B Market by 2030 Lung cancer remains the leading cause of cancer deaths worldwide, with a desperate need for innovative solutions. The global lung cancer therapeutics market is projected to exceed $52.21B by 2030, paving the way for transformative treatments to address critical needs. Linebacker, with its ability to target and disrupt critical cancer-driving pathways, offers innovative therapeutic options both as a monotherapy and in combination therapies. Colon Cancer: Tackling Challenges in a $16.7 Billion Market by 2030 The global colorectal cancer therapies market is expected to reach $16.7B by 2030, fueled by rising prevalence and unmet medical needs. Linebacker’s precise disruption of key molecular mechanisms in cancer progression positions it as a game-changing treatment for one of the deadliest cancers worldwide. Neurology: Advancing Solutions in a $69.8B Global Market by 2030 Neurological diseases like Alzheimer’s and Parkinson’s represent some of the most complex medical challenges. The global market for neurological disease treatments is anticipated to reach $69.8B by 2030, emphasizing the urgent need for new solutions. Linebacker’s anti-inflammatory and neuroprotective properties make it a strong contender in the treatment of neurodegenerative conditions, offering hope where few viable options exist. Equivir: Driving Innovation in the Antiviral Market Set to Reach $51.46B by 2030 As the global antiviral therapeutics market is projected to exceed $51.46B by 2030, Impact BioMedical Inc. (NYSE: IBO)’s Equivir emerges as a timely and scalable solution. This advanced polyphenol-based formulation is engineered to combat a wide range of viral infections while supporting immunity. Key Applications of Equivir Upper Respiratory Infections: Equivir addresses billions of annual upper respiratory infection cases globally, offering both treatment and preventative solutions. Immunity-Boosting Supplements: With its natural composition, Equivir provides a sustainable and effective option for boosting immunity, aligning with growing consumer demand for preventative health products. Equivir combines FDA Generally Recognized as Safe (GRAS) ingredients like myricetin and piperine, delivering high efficacy without compromising safety. 3F Functional Fragrances: Everyday Protection Meets Advanced Science The 3F platform combines cutting-edge biochemistry with practical applications to offer dual-layer protection in consumer products. Combatting Vector-Borne Diseases Vector-borne diseases account for over 17% of global infectious illnesses, posing a significant threat to public health. 3F uses botanical-derived terpenes to create natural, effective insect repellents that protect against mosquitoes and other vectors carrying diseases like malaria and dengue. Antiviral Properties in Everyday Products 3F formulations provide an additional biochemical barrier against pathogens when integrated into products such as shampoos, lotions, and detergents. These formulations protect consumers while seamlessly fitting into their daily routines, exemplifying how science and practicality can align. With patents secured through 2040, 3F Functional Fragrances is poised to make a significant impact in the global wellness market. Laetose: Disrupting the $16 Billion Sugar Substitute Market Consumer demand for healthier alternatives to sugar is driving the global sugar substitute market, which is valued at $16 billion. Impact BioMedical Inc. (NYSE: IBO)’s Laetose offers an innovative solution that reduces caloric intake and mitigates glycemic response while maintaining sweetness. Health and Wellness Applications Lower Calorie Impact: Laetose addresses the rising demand for low-calorie options among health-conscious consumers. Anti-Inflammatory Properties: Beyond being a sugar substitute, Laetose’s unique composition also taps into the inflammatory disease treatment market, which is expected to reach $133.96B by 2030, offering additional health benefits for metabolic and inflammatory conditions. This innovative formulation combines sugars with inositol to provide a satisfying and healthier alternative to traditional sweeteners. Driving Innovation Across High-Growth Global Markets Impact BioMedical Inc. (NYSE: IBO) isn’t just delivering products—it’s redefining health and wellness through transformative solutions that meet unmet needs in global markets. With 39 issued patents and 50 pending applications worldwide, the company is setting new benchmarks in healthcare innovation. Strategic Collaborations to Maximize Impact Collaborations with industry leaders such as ProPhase Labs and Chemia Corp amplify the company’s ability to bring these cutting-edge technologies to global markets efficiently. From oncology and neurology to antivirals and wellness products, Impact BioMedical Inc. (NYSE: IBO) is driving innovation in high-value global markets while making a tangible difference in human health. Leading the Future of Global Health Impact BioMedical Inc. (NYSE: IBO) is not just innovating; it’s creating real-world solutions that address critical global health challenges. With a clear vision, cutting-edge science, and a robust intellectual property portfolio, the company is positioned to transform the future of healthcare and consumer wellness. 5 reasons to add Impact BioMedical Inc. (NYSE: IBO)  to your radar this morning… 1. Robust Intellectual Property Portfolio: With 39 issued patents and 50 pending applications, the company’s technologies are protected globally, ensuring a strong competitive edge. 2. Recent Market Momentum: With shares moving approximately 120% in just one month and a recent IPO, this company is already gaining significant traction and attention. 3. Limited Float: A low float of under 5.1M shares creates the potential for the company to be highly responsive to shifts in demand, which could lead to significant swings.  4. Targeting High-Growth Industries: The company is addressing markets collectively valued at over $324B by 2030, including oncology, neurology, antivirals, and sugar substitutes. 5. Successful IPO: The company’s recent listing on the NYSE American exchange reflects strong confidence in its growth strategy, positioning it for enhanced visibility and access to resources for future expansion.  Impact BioMedical Inc. (NYSE: IBO) is capturing significant market attention with its successful IPO and impressive recent performance, including an approximate 120% share movement in just one month. A limited float of under 5.1M shares underscores Impact BioMedical Inc. (NYSE: IBO)’s potential for significant swings if demand begins to shift, while its focus on high-growth industries like oncology, neurology, and consumer wellness reflects a bold vision.  Backed by a robust intellectual property portfolio and strategic collaborations, Impact BioMedical Inc. (NYSE: IBO) is driving cutting-edge solutions that could redefine global health and wellness markets. We’ll be covering Impact BioMedical Inc. (NYSE: IBO) this morning so make sure you take a look at it early. I’ll circle back with you shortly. But in the meantime, pull up (IBO). Sincerely, Gary Silver Managing Editor, MarketCrux MarketCrux.com (“MarketCrux” or “MC” ) is owned by Headline Media LLC, a multi member limited liability company. Data is provided from third-party sources and MarketCrux is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MC brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors. The owners of Headline Media LLC own and operate marketcrux . com (“MC”). From time to time, MC will publicly disseminate information about a company via website, email, SMS and other points of media. Please see important disclosure information here: marketcrux.com/disclaimer/  *Pursuant to an agreement between Headline Media LLC and TD Media LLC, Headline Media LLC has been hired by TD Media LLC for a period beginning on 11/17/2024 and ending on 11/18/2024 to publicly disseminate information about (IBO:US) via digital communications. Under this agreement, Headline Media LLC has been paid ten thousand USD (“Funds”) to disseminate information about (IBO:US) via digital communications. These Funds were part of the funds that TD Media LLC received from a third party who did not receive the funds from the issuer and does not own stock in the issuer but the reader should assume that the clients of the third party own shares in the issuer that they will liquidate at or near the time you receive this communication, which has the potential to hurt share prices. Neither Headline Media or its members own shares of (IBO:US). Please see important disclosure information here: https://marketcrux.com/disclosure/ibo/

Headline Media | 7901 4th Street N Suite 300 | St. Petersburg, FL 33702 US Unsubscribe | Update Profile | Constant Contact Data Notice